October 1 2020 - Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Flag link:
Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Fierce Pharma
congress
drug pricing
Novartis
Amgen
Mallinckrodt
Flag link:
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
Alnylam Posts Positive Results of Groundbreaking Phase III PH1 Trial
BioSpace
Alnylam
lumasiran
clinical trials
Primary Hyperoxaluria
Flag link:
A second Carl Icahn protégé jumps in on SPAC spree, as Alex Denner guns for $175M
A second Carl Icahn protégé jumps in on SPAC spree, as Alex Denner guns for $175M
Endpoints
SPAC
Sarissa Capital
Flag link:
Bidding to be the go-to genomics and data partner for drug development, Sophia Genetics raises $100M
Bidding to be the go-to genomics and data partner for drug development, Sophia Genetics raises $100M
Endpoints
Sophia Genetics
genomics
drug development
Flag link:
CPhl event to draw attention to M&A activity in gene and cell sector
CPhl event to draw attention to M&A activity in gene and cell sector
Biopharma Reporter
M&A
gene therapy
cell therapy
CPhI
Flag link:
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
Feds target Medtronic in ventilator antitrust investigation
Feds target Medtronic in ventilator antitrust investigation
Mass Device
Medtronic
devices
ventilators
federal government
antitrust
Flag link:
FDA expands probe into safety of AstraZeneca's COVID-19 vaccine
FDA expands probe into safety of AstraZeneca's COVID-19 vaccine
Fierce Biotech
FDA
safety
AstraZeneca
COVID-19
vaccines
clinical trials
Flag link:
Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer
Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer
Endpoints
Lysosomal Therapeutics
Allergan
R&D
M&A
Henri Termeer
Bial
Flag link:
More biotechs test the third way to market
More biotechs test the third way to market
EP Vantage
biotech
SPAC
IPOs
Flag link:
Drug costs aren't the main reason US spends so much on healthcare, study finds
Drug costs aren't the main reason US spends so much on healthcare, study finds
Beckers Hospital Review
drug pricing
drug costs
healthcare costs
physicians
Flag link:
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
RAPS.org
congress
Celgene
Teva Pharmaceutical
Revlimid
Copaxone
drug pricing
Flag link:
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
Pharmaforum
Vedanta Biosciences
microbiome
C. difficile
BARDA
Flag link:
Moderna Coronavirus Vaccine Won't Be Available Before Election Day, CEO Says
Moderna Coronavirus Vaccine Won't Be Available Before Election Day, CEO Says
Motley Fool
Moderna Therapeutics
vaccines
COVID-19
2020 Presidential election
Flag link:
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries
Xconomy
Genfit
NASH
restructuring
layoffs
Flag link:
Smith & Nephew to Buy Integra Unit for $240M Cash
Smith & Nephew to Buy Integra Unit for $240M Cash
Medical Devices and Diagnostics Industry
Smith & Nephew
M&A
Orthopedics
Integra LifeSciences
devices
Flag link:
Arranta Bio set to boost manufacturing for growing pipeline of microbiome drugs
Arranta Bio set to boost manufacturing for growing pipeline of microbiome drugs
BioPharma Dive
Arranta Bio
microbiome
CDMO
drug manufacturing
Flag link:
J&J, Pfizer comms chiefs talk vaccine pledge, politics, inequality and getting to a 'better normal'
J&J, Pfizer comms chiefs talk vaccine pledge, politics, inequality and getting to a 'better normal'
Fierce Pharma
JNJ
Pfizer
vaccines
politics
reputation
Flag link:
Ovid shows mixed results on epilepsy program
Ovid shows mixed results on epilepsy program
Endpoints
Ovid Therapeutics
clinical trials
epilepsy
Flag link:

Pages